-
Friday General Session features late-breaking data from KATHERINE and INAVO120 clinical trials
Findings from 11 studies were presented Friday during the third and final General Session of the 2023 SABCS®.
LATEST FROM THE 2023 SYMPOSIUM
-
AACR Outstanding Investigator outlines need for better metastatic breast cancer models
Alana L. Welm, PhD, on Friday discussed what she was doing to model metastatic breast tumors using patient-derived xenografts and organoids, and she implored her fellow researchers to work together to advance the field.
-
Panelists explore challenging, unresolved breast cancer questions based on real-world case studies
Audience members brought real-world clinical cases and concerns before a multidisciplinary panel on Thursday, prompting discussions about choosing optimal care and treatment for patients with breast cancer in routine practice.
-
Panel underscores utility, importance of molecular/genomic testing in breast cancer practice
Pedram Razavi, MD, PhD, moderated a Wednesday session that leveraged challenging, complex clinical cases to highlight how the range of expertise of a molecular tumor board (MTB) can inform and help optimize patient care and treatment in real-world practice.
-
AACR distinguished lecturer a pioneer in intratumoral heterogeneity
AACR Distinguished Lectureship recipient Kornelia Polyak, MD, PhD, FAACR, on Thursday discussed her work on disease transition and profiling the different cell types involved in different stages of breast disease.
-
Basic science workshop demonstrates potential of organoids, genomic data, computational biology
Presenters including Calvin J. Kuo, MD, PhD, discussed basic science developments such as the role of organoids, single-cell sequencing, clinical genomics, and molecular docking.
-
Career Development Forum offers new opportunities for early-career scientists
Saturday morning’s Career Development Forum, for preregistered attendees, will feature concurrent workshops focusing on clinical trials, grant writing, and career goals.
-
Thursday General Session includes findings from NRG Oncology/NSABP B-51/RTOG 1304 and other trials
Findings from 10 studies, including IDEA, PREFERABLE-EFFECT, and POSITIVE, were presented Thursday during the second General Session of the 2023 SABCS®.
-
SABCS® Daily Highlights for Friday, December 8
SABCS® Program Director Kate Lathrop, MD, shares a few highlights from Friday’s schedule to help you plan your day, including notable presentations, award lectures, and more.